Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / SPHRF - Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack

SPHRF - Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack

Starpharma Holdings Ltd
  • Merck/Ridgeback Bio partnership on tablet form of antiviral molnuparivir attracts US Government interest for early-stage COVID treatment.
  • Starpharma’s Viraleze for prevention and early-stage COVID treatment as a nasal spray gets traction in Europe and India.
  • Monoclonal antibody-based treatments are more speculative and likely to be very expensive.
  • Investment in early-stage treatments limited as Ridgeback Bio is private and Merck too big for molnuparivir to affect its share price. Opportunity with Starpharma (Viraleze and other areas) as it is unloved currently.

For further details see:

Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack
Stock Information
Company Name: Starpharma Holdings Ltd
Stock Symbol: SPHRF
Market: OTC
Website: starpharma.com
Menu
SPHRF SPHRF Quote SPHRF Short SPHRF News SPHRF Articles SPHRF Message Board
Get SPHRF Alerts

News, Short Squeeze, Breakout and More Instantly...